Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have received an average recommendation of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.50.

A number of equities research analysts have recently weighed in on ENTA shares. JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. JPMorgan Chase & Co. decreased their price target on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research note on Tuesday, August 6th. Robert W. Baird lowered their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. Finally, Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, August 6th.

Enanta Pharmaceuticals Stock Down 2.6 %

Shares of NASDAQ:ENTA opened at $8.60 on Friday. The company’s 50-day moving average price is $10.81 and its 200 day moving average price is $12.24. The company has a market cap of $182.23 million, a PE ratio of -1.57 and a beta of 0.56. Enanta Pharmaceuticals has a fifty-two week low of $8.00 and a fifty-two week high of $17.80.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC acquired a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at $35,000. US Bancorp DE lifted its holdings in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 4,243 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at about $191,000. Quest Partners LLC grew its stake in shares of Enanta Pharmaceuticals by 511.2% in the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 9,692 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter worth approximately $122,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.